CEPHALON MYOTROPHIN NDA FILING PLANS UNCHANGED AFTER COMMITTEE REVIEW; EUROPEAN TRIAL UNSUPPORTIVE OF FIRST PHASE III, FDA AND COMMITTEE AGREE
Executive Summary
Cephalon is staying with to its plans to file an NDA for Myotrophin for treatment of amyotrophic lateral sclerosis this summer, the company said June 10.